Ending a grueling 10-year drought, Sanofi finally wins an OK for an in-house cancer drug
Sanofi has snagged an FDA approval for a top drug in its pipeline, ending a 10-year drought of home-grown cancer drug approvals as the new team in charge looks to reboot one of the industry’s perpetual laggards.
The agency stamped an early OK on isatuximab, a CD38 drug that will now begin a market rivalry with J&J’s market leading Darzalex under the name Sarclisa. It’s approved as a 3rd line treatment for multiple myeloma.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.